AHA Coding Clinic® for HCPCS - 2012 Quarter 3; For Your Information
New HCPCS Codes for Certain Drugs and Biologicals
CMS has created five new HCPCS codes for the reporting of certain drugs and biologicals (other than new pass-through drugs and biologicals). These codes became effective July 1, 2012 and are listed in the next column. HCPCS Code Long Descriptor Q2045 * Injection, human, fibrinogen concentrate, 1 mg Q2046 ** Injection, aflibercept, 1mg Q2048 *** Injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg Q2049 Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu) *Effective since July 1, 2012, Level II HCPCS code J1680 , Injection, human fibrinogen concentrate, 100 mg, was replaced...
Subscribe or sign in to view the full article.
Article Overview
This article covers CMS guidance on newly created HCPCS Level II reporting codes for selected drugs and biologicals, effective July 1, 2012. It is relevant to medical coders, billing staff, compliance teams, and reimbursement professionals who track annual code changes and code replacements. The article also notes related prior code changes and identifies the affected products in a general way.
Why This Topic Matters
Updates to HCPCS code sets can affect charge capture, claims reporting, and continuity of coding when existing codes are replaced or deleted. Reviewing these changes helps organizations stay aligned with current CMS reporting requirements.
What You Will Learn
- Which general category of HCPCS updates CMS issued
- Which types of drug and biological reporting changes are discussed
- How the article frames effective dates and code replacements
- What kinds of products were included in the update notice
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Compliance professionals
- Pharmacy billing teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com